Dr. Praveen Chandra

Chairman

39 Years of Experience

Interventional Cardiologist

MBBS, MD, DM, FIC, FACC, FAPSIC, FSCAI, FESC, FEISI

Reg. No.:4939, Haryana State Dental Council

Medanta - The Medicity Hospital, Gurgaon

English

Consultation Fee ₹ 1500

Book an Appointment

About Dr. Praveen Chandra

Dr. Praveen Chandra stands as a distinguished figure in the field of Interventional Cardiology within India, renowned for his profound expertise and pioneering advancements in interventional cardiology.
With an extensive career spanning 39, Dr. Chandra conducts over 5000 percutaneous and diagnostic interventions annually, showcasing his vast experience and skill.
He specializes in innovative techniques aimed at minimizing the necessity for open-heart surgeries.
He notably executed the first Percutaneous Aortic Valve implantation without surgery in India.
Dr. Chandra is credited with the development of methodologies aimed at reducing the requirement for bypass surgeries, alongside enhancing the accuracy of angioplasty procedures for treating multiple blocked arteries.
His groundbreaking utilization of the Fractional Flow Reserve (FFR) technique on a 78-year-old patient garnered widespread recognition, earning him a feature in The Times of India.
Frequently sought after as a keynote speaker and faculty member at conferences, Dr. Chandra actively shares his insights and presents his research findings, organizing seminars and meetings to foster advancements in interventional cardiology.
His educational journey started with MBBS from King George's Medical College, Lucknow University, 1985, followed by MD (Medical Genetics) from King George's Medical College, Lucknow University, 1989, and DM (Cardiology) from King George's Medical College, Lucknow University, 1991.
Dr. Chandra also achieved various fellowships including that of Interventional Cardiology University of Rouen, France, 1995, American College of Cardiology, 2006, Asia-Pacific Society of Interventional Cardiology, 2006, Society of Cardiovascular Angiography and Intervention, 2006, European Society of Cardiology, 2007, and Endovascular Intervention Society of India.
Acknowledged for his monumental contributions, particularly in the realm of coronary angioplasty, Dr. Chandra has received numerous accolades.
A pivotal member of the pioneering team in Asia that initiated the Percutaneous Myocardial Laser Revascularization Program, his impact on the field is undeniable.
Dr. Chandra boasts a prolific publication record, with over 100 publications comprising abstracts, articles, and papers in esteemed national and international medical journals.
He is an active member of the Cardiological Society of India (CSI) and the American College of Cardiology.

Book Your Appointment With Dr. Praveen Chandra

Get a Treatment Plan Within 1 Hour

Name*

Mobile Number*

Is the above number on WhatsApp? *

Yes

Query

Education

MBBS, King George's Medical College, Lucknow University, 1985
MD (Medical Genetics), King George's Medical College, Lucknow University, 1989
DM (Cardiology) King George's Medical College, Lucknow University, 1991
Fellow Interventional Cardiology University of Rouen, France (FIC), 1995
Fellow of the American College of Cardiology (FACC), 2006
Fellow of the Asia-Pacific Society of Interventional Cardiology (FAPSIC), 2006
Fellow of the Society of Cardiovascular Angiography and Intervention (FSCAI), 2006
Fellow of the European Society of Cardiology (FESC), 2007
Fellow of the Endovascular Intervention Society of India (FEIS)

Past Experience

Director, Max Heart & Vascular Institute, Saket, New Delhi, India, 2010
Senior Consultant, Escorts Heart Institute and Research Center, New Delhi, India, 2004
Senior Resident, King George Medical College, 1992
Senior Resident, King George Medical College, 1989
House Officer, King George Medical College, 1987
Internship Trainee, King George Medical College, 1986

Awards

Recognition Award for Success and achievement in the field of angioplasty in India - 1998
Padma Shri Award - 2016

Associations/Membership

Cardiological Society of India (CSI)
American College of Cardiology

Paper Published

Dr. Praveen Chandra has over 100 publications to his name, some of which are mentioned below:
- Safety and effectiveness of the novel Myval Octacor transcatheter heart valve in severe, symptomatic aortic valve stenosis — A real-world Indian experience (The OCTACOR India Study).
- Angiographic quantification of aortic regurgitation following myval octacor implantation; independent core lab adjudication.
- Clinical expert consensus document on the use of percutaneous left ventricular assist devices during complex, high-risk PCI in India using a standardized algorithm.
- Clinical evaluation of the Hydra self?expanding transcatheter aortic valve: 6-month results from the GENESIS trial.
- Evaluation of Balloon Expandable Transcatheter Heart Valve in the Treatment of Severe Symptomatic Native Aortic Stenosis: The First-in-human MyVal-1 Study.
- First-in-Human Evaluation of Balloon Expandable Transcatheter Heart Valve in the Treatment of Severe Symptomatic Native Aortic Stenosis: The MyVal-1 Study.
- Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial.
- Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System for Treatment of De Novo Native Coronary Lesions: A Sub-Study of MeRes-1 Trial.
- TCT-64 Two-Year Clinical and Imaging Outcomes of Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffolds in De Novo Coronary Artery Lesions: The MeRes-1 Trial.
- First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial.
- TCTAP A-003 First-in-human Evaluation of a Novel Poly-L-lactide Based Sirolimus-eluting Bioresorbable Vascular Scaffold for the Treatment of De Novo Native Coronary Artery Lesions: MeRes-1 Trial
- TCTAP A-058 Favorable Outcomes for Systemic Pharmacokinetic Study of Sirolimus-eluting Bioresorbable Vascular Scaffold System in Treating De Novo Native Coronary Artery Lesion: A Sub Study of MeRes-1 Trial.
- CRT-700.01 Favourable Outcomes for Systemic Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System in Treating de novo Native Coronary Artery Lesion: A Sub Study of MeRes-1 Trial.
- Clinical Characteristics and Outcomes after Unplanned Intra aortic Balloon Counterpulsation in the Counterpulsation to Reduce Infarct Size Pre-PCI Acute Myocardial Infarction Trial.
- A prospective, multicenter, post-marketing surveillance study to evaluate the safety and effectiveness of the Superia-Sirolimus Eluting Coronary Stent System (SSECSS) implanted during routine clinical practice in India.